VERAXA Biotech AG Advances Toward NASDAQ Listing with Form F-4 Filing

VERAXA Biotech AG, a company within the portfolio of Xlife Sciences AG, has taken a critical step towards its NASDAQ listing by filing Form F-4 with the U.S. Securities and Exchange Commission. The filing is a significant milestone in the journey of becoming a publicly listed company. It details its business combination with Voyager Acquisition Corp., a SPAC listed on NASDAQ.

This business combination will see VERAXA contributing approximately $1.3 billion in equity value, with its shareholders receiving around 130 million ordinary shares of the merged entity. No cash proceeds will be distributed to existing shareholders who are set to transfer all their equity into the new company.

VERAXA is also raising additional funds through a crossover financing round. Upon closing, expected in Q4 2025, VERAXA anticipates gaining access to $253 million, enhancing its valuation considerably. This move underlines VERAXA's position in the oncology therapeutics market.